WhatPeptide

HGH Fragment 176-191

HGH Fragment 176-191 is the C-terminal peptide fragment of human growth hormone specifically associated with lipolytic activity, studied for fat loss without the growth-promoting or insulin-desensitizing effects of intact HGH. It is distinct from AOD-9604 which is a modified version with additional structural changes.

Preliminary evidence Unregulated GH Fragment

Written by WhatPeptide Editorial Team · Last updated 2026-03-17

Half-life

Approximately 30 minutes

Dosage range

200-500 mcg subcutaneously 1-2x daily fasted (published research context)

Administration

Subcutaneous injection

Research level

Preliminary

How HGH Fragment 176-191 works

HGH Fragment 176-191 stimulates lipolysis through beta-adrenergic-like mechanisms involving adenylyl cyclase activation in adipocytes, mimicking the fat-mobilizing region of native HGH. Unlike full-length growth hormone, the fragment does not bind the GH receptor with sufficient affinity to stimulate IGF-1 production or promote cellular proliferation, confining its action predominantly to adipose tissue. Preclinical data supports selective fat oxidation, but clinical evidence in humans remains limited to small exploratory studies.

Also known as: HGH Frag 176-191, AOD-9176, GH Fragment

Research relevance

Fat Loss
Moderate relevance 65

Side effects & safety

Injection site irritation Headache Hypoglycemia risk if administered with carbohydrates

Contraindications

Active malignancy
Diabetes requiring tight glucose management
Pregnancy

Consult a healthcare provider before use if any of these apply to you.

Key studies

FAQ

What is HGH Fragment 176-191? +
HGH Fragment 176-191 is the C-terminal peptide fragment of human growth hormone specifically associated with lipolytic activity, studied for fat loss without the growth-promoting or insulin-desensitizing effects of intact HGH. It is distinct from AOD-9604 which is a modified version with additional structural changes. Its mechanism of action is based on preliminary or early-stage research.
What is HGH Fragment 176-191 researched for? +
HGH Fragment 176-191 has the strongest research relevance for Fat Loss. Evidence is based on preliminary or early-stage research.
What are the side effects of HGH Fragment 176-191? +
Reported side effects include Injection site irritation, Headache, Hypoglycemia risk if administered with carbohydrates. Key contraindications: Active malignancy; Diabetes requiring tight glucose management; Pregnancy.
Is HGH Fragment 176-191 FDA approved? +
HGH Fragment 176-191 is not FDA-approved. It is available as a research compound or through compounding pharmacies in some jurisdictions.
How is HGH Fragment 176-191 administered? +
HGH Fragment 176-191 is typically administered via subcutaneous route. Researched dosage range: 200-500 mcg subcutaneously 1-2x daily fasted (published research context). Half-life: Approximately 30 minutes.

Explore similar peptides

AOD-9604

Preliminary evidence

GH Fragment

A modified growth hormone fragment investigated for lipolysis-related effects without full GH receptor profile. Originally placed on FDA Category 2 list (September 2023), then removed September 27, 2024 when the nominator withdrew. FDA still lists it under 'Other bulk drug substances that may present significant safety risks.' Regulatory status remains uncertain.

5-Amino-1MQ

Preliminary evidence

Metabolic

5-Amino-1MQ is a small-molecule NNMT inhibitor studied in preclinical obesity and metabolic syndrome models for its ability to reduce fat mass and improve metabolic parameters. It has shown promise in rodent studies for promoting leanness without apparent toxicity at research doses.

Adipotide

Preliminary evidence

Metabolic

A synthetic chimeric peptidomimetic (~2,611 Da) that destroys white adipose tissue vasculature. Its CKGGRAKDC homing motif binds prohibitin/annexin A2 on WAT blood vessels, while the D(KLAKLAK)₂ domain triggers mitochondrial apoptosis in those endothelial cells. Developed at UT MD Anderson; Phase 1 trial (NCT01262664) terminated with no published results.

BAM-15

Animal studies only

Exercise Mimetic

A mitochondrial protonophore uncoupler with EC₅₀ 1.4 μM (~7× more potent than DNP at 10.1 μM). Developed through a multi-institutional collaboration: Webster Santos at Virginia Tech and Kyle Hoehn at the University of Virginia (later UNSW Sydney). Selectively accumulates in lipid-rich tissues (liver, adipose). In mice, reversed diet-induced obesity without hyperthermia or reduced food intake. Continuum Biosciences (co-founded by Santos and Hoehn, 2017) is developing it.